Skip to main content

Table 2 The best overall response (N = 42) in patients treated with biweekly SOX

From: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study

The best response (N = 42) No. (%)
CR 0 (0%)
PR 22 (52.5%)
SD 14 (33.3%)
PD 6 (14.3%)
ORR (CR + PR) 22 (52.5%)
DCR (CR + PR + SD) 36 (85.7%)
  1. CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Objective response rate, DCR Disease control rate